Kezar Life Sciences Files 8-K on Financials

TL;DR

Kezar Life Sciences (KZR) filed an 8-K on Jan 10, 2025, updating investors on its financial results.

AI Summary

Kezar Life Sciences, Inc. filed an 8-K on January 10, 2025, reporting on its Results of Operations and Financial Condition. The filing details the company's status as a Delaware corporation with its principal executive offices located in South San Francisco, California.

Why It Matters

This 8-K filing provides an update on Kezar Life Sciences' financial condition and operational results, which is crucial information for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

• Kezar Life Sciences, Inc. (company) — Registrant
• January 10, 2025 (date) — Date of earliest event reported
• South San Francisco, California (location) — Principal Executive Offices
• 4000 Shoreline Court, Suite 300 (address) — Business and Mail Address

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value KZR The Nasdaq Stock Market L
• $132.2 million — of December 31, 2024 were approximately $132.2 million and that it had 7.3 million shares of c

Filing Documents

• kzr-20250110.htm (8-K) — 25KB
• 0001645666-25-000001.txt ( ) — 192KB
• kzr-20250110.xsd (EX-101.SCH) — 3KB
• kzr-20250110_def.xml (EX-101.DEF) — 16KB
• kzr-20250110_lab.xml (EX-101.LAB) — 29KB
• kzr-20250110_pre.xml (EX-101.PRE) — 17KB
• kzr-20250110_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. Kezar Life Sciences, Inc. (the "Company") preliminarily estimates that its cash, cash equivalents and marketable securities as of December 31, 2024 were approximately $132.2 million and that it had 7.3 million shares of common stock outstanding as of December 31, 2024. These preliminary estimates are not a comprehensive statement of the Company's financial results for the year ended December 31, 2024 and have not been audited, reviewed, or compiled by its independent registered public accounting firm. The Company's actual consolidated cash, cash equivalents and marketable securities balance and shares of common stock outstanding as of December 31, 2024 may differ from these estimates due to the completion of the Company's year-end closing and auditing procedures. The information provided in this Item 2.02 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEZAR LIFE SCIENCES, INC. Date: January 10, 2025 By: /s/ Marc L. Belsky Marc L. Belsky Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR